Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Arnhem – page 53

787 clinical trials in Arnhem, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Arnhem at a glance
787
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

787 trials in Arnhem

Open in trial search

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Prostate cancer

Not recruiting

Study of Pembrolizumab, Vibostolimab, and Belzutifan for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Merck Sharp & Dohme LLC

Ovarian cancer stage IV+1

Not recruiting

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Tesaro Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Cervix carcinoma

Not recruiting

Study on Tisotumab Vedotin, Bevacizumab, Carboplatin, and Pembrolizumab for Patients with Recurrent or Stage IVB Cervical Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Colon cancer stage II+1

Not recruiting

Study on Adjuvant Therapy with Capecitabine for Stage II Colon and Rectal Cancer Patients with Positive ctDNA After Tumor Removal

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Technische Universitat Dresden

Study on Imaging Lung Aspergillosis Using Gallium-68 Deferoxamine for Patients with Pulmonary Aspergillosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Deferoxamine Mesilate
  • Sponsor:Radboud universitair medisch centrum Stichting

Myotonic dystrophy

Not recruiting

Safety and effectiveness study of DYNE-101 in patients with Myotonic Dystrophy Type 1 (DM1)

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Sponsor:Dyne Therapeutics Inc.

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Daiichi Sankyo Inc.

B-cell lymphoma+1

Not recruiting

Study on Epcoritamab, Rituximab, and Lenalidomide for Adults with Untreated Follicular Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effect of Hyperthermic Intraperitoneal Chemotherapy with Cisplatin for Stage III Ovarian Cancer Patients Undergoing Surgery

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Study on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Arnhem

What the registry says about research in the country

01 Oncology Studies

Innovative research focusing on advanced gastric cancer, bladder cancer, and various forms of leukemia. Studies include evaluation of novel imaging techniques and combination therapies for better treatment outcomes.

  • Gastric Cancer Staging
  • Bladder Cancer Therapeutics
  • Acute Myeloid Leukemia Treatment

Multiple trials exploring targeted therapies and innovative diagnostic approaches for various cancer types.

02 Cardiovascular Research

Comprehensive studies addressing cardiovascular disease management and prevention, including research on post-stroke care and cardiac arrest treatments.

  • Stroke Treatment Protocols
  • Cardiac Arrest Management
  • Cardiovascular Risk Reduction

Focus on improving patient outcomes through innovative therapeutic approaches and prevention strategies.

03 Metabolic Disorders

Clinical investigations targeting obesity and weight management, with emphasis on new therapeutic agents and their cardiovascular safety profiles.

  • Weight Management Therapies
  • Metabolic Disease Treatment
  • Safety Assessments

Evaluating novel approaches to treating metabolic disorders and their associated complications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.